Work

Real-world outcomes among patients with metastatic castration-resistant prostate cancer (mCRPC) receiving guideline-recommended therapies after treatment with 177 Lu-PSMA-617: A real-world prostate cancer disease observation (PRECISION) data platform analysis.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.61

Authors: Xiao X. Wei, Neal D. Shore, Daniel J. George, Elisabeth I. Heath, Jennifer Nguyen, Jeetvan Patel, Amrita Sawhney, Barinder Kang, Clare Byrne, Jackson Tang, Alton Oliver Sartor

Institutions: Dana-Farber Cancer Institute, Carolina Urologic Research Center, Duke University, Duke Medical Center, Duke Cancer Institute, The Barbara Ann Karmanos Cancer Institute, Mayo Clinic

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Novartis Pharmaceuticals Corporation

OpenAlex ID: W4407701356

Cites:

Cited by: 1

Related to: 10